LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Get ready, folks! This newsletter is going to be veeeery long and packed with news. This year too, the ESMO conference brings us plenty of updates, both on clinical trials and on preclinical and observational studies. Stay strong and fight on! […]
Data from the phase 3 EMBARK trial, combining enzalutamide with standard hormone therapy, recently published in The New England Journal of Medicine and presented at the 2025 European Society for Medical Oncology (ESMO) Congress, reveal that this combination reduces the risk of death by more than 40% over eight years compared to hormone therapy alone. […]
The investigational drug ENV-105 (carutoximab), a first-in-class CD105 antagonist, has shown promising interim efficacy results in a Phase 2 clinical trial involving patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after standard hormone therapies. This ongoing trial evaluated the combination of ENV-105 with apalutamide, a commonly used hormone therapy. Among patients treated, 86% […]
KLS-3021 is a novel oncolytic virus therapy developed for the treatment of prostate cancer. It employs a recombinant vaccinia virus engineered to selectively infect and destroy cancer cells while activating the immune system to target tumors more effectively. The virus carries three therapeutic genes: PH-20, which degrades the extracellular matrix to facilitate viral spread and […]
At the ESMO Congress 2025 held in Berlin, artificial intelligence demonstrated a pivotal role in reshaping cancer treatment through novel biomarker applications. Studies presented at this event showed how AI models analyzing pathology images, imaging data, and genomic profiles can improve predictions of patient responses to therapies. For example, in metastatic colorectal cancer, AI identified […]
At the 2025 ESMO Congress, interesting data was presented showing that mRNA-based COVID-19 vaccines significantly improve outcomes for cancer patients undergoing immunotherapy. This large retrospective study, conducted by MD Anderson Cancer Center in collaboration with the University of Florida, analyzed clinical data from over 1,000 patients with various types of cancer treated between 2019 and […]
Gedatolisib, an inhibitor targeting the PI3K/AKT/mTOR pathway, in combination with darolutamide, an androgen receptor antagonist, is being evaluated as a treatment option for metastatic castration-resistant prostate cancer (mCRPC). In a phase 1/2 clinical trial, patients who had progressed on prior androgen receptor signaling inhibitors received once-weekly intravenous gedatolisib in doses of 120 mg or 180 […]
At the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, new clinical data from a Phase 1b dose escalation trial investigating ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) was presented. The therapy utilizes a radioactive isotope, Lead-212, to deliver targeted alpha radiation to prostate cancer cells, aiming […]
The PRESTO trial, a phase 3 open-label study, evaluated androgen blockade intensification in patients with high-risk biochemically relapsed prostate cancer after radical prostatectomy. This population featured rapid PSA doubling times and no detectable metastases. The study randomized 504 patients to 52 weeks of treatment with either androgen deprivation therapy (ADT) alone, ADT plus apalutamide, or […]
The final results of the phase 3 ENZARAD study, presented at the European Society for Medical Oncology (ESMO) Congress 2025, reveal that intensifying androgen deprivation therapy (ADT) with enzalutamide does not significantly improve metastasis-free survival (MFS) in the overall population of men with high-risk localized or locally advanced prostate cancer. Conducted across eight countries and […]